{
    "clinical_study": {
        "@rank": "78805", 
        "acronym": "ARC", 
        "arm_group": [
            {
                "arm_group_label": "Rivaroxaban", 
                "arm_group_type": "Active Comparator", 
                "description": "Anticoagulation with Rivaroxaban 20 mg daily with dinner for 30 days"
            }, 
            {
                "arm_group_label": "Warfarin and  Enoxaparin", 
                "arm_group_type": "Other", 
                "description": "Warfarin: 1-10 mg per Nomogram Enoxaparin weight based 1 mg/kg Q12 or 1.5 mg/kg/day Historic control"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine that a new drug called \"Rivaroxaban\u00ae\" is effective\n      in preventing patients from forming clots after their heart rhythm has been reset by the\n      cardiologist with an electrical device."
        }, 
        "brief_title": "Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Atrial Fibrillation", 
            "Stroke", 
            "Thrombo-embolism", 
            "Bleeding"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Atrial Fibrillation", 
                "Embolism", 
                "Hemorrhage", 
                "Stroke", 
                "Thromboembolism"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patient who are electrically cardioverted require 1 month of anticoagulation (blood\n      thinner). Rivaroxaban a Xa-inhibitor has been shown to be non-inferior to Warfarin (Vit K\n      antagonist) the current standard of care in many treatment areas. Rivaroxaban will be\n      compared to Warfarin historical control group studying the safety and efficacy in\n      electrically cardioverted patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with non-valvular atrial fibrillation requiring electrical cardioversion o\n             Atrial fibrillation of unknown duration\n\n        Exclusion Criteria:\n\n          -  Patients requiring extended anticoagulation after cardioversion due to concomitant\n             risk factors as defined by CHADS2 score \u2265 1\n\n          -  Significant renal dysfunction (CrCl <15mL/min)\n\n          -  Significant hepatic dysfunction (Childs-Pugh Class B or C)\n\n          -  History of coagulopathy\n\n          -  Active bleeding\n\n          -  Hypersensitivity to Rivaroxaban\n\n          -  Concomitant use of anticoagulants\n\n          -  Concomitant use of potent CYP3A4/P-gp inhibitors or inducers\n\n          -  Interventions requiring interruption of therapy\n\n          -  Pregnancy\n\n          -  Age <18 y/o\n\n          -  History of GI Bleed"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01747746", 
            "org_study_id": "12-139"
        }, 
        "intervention": [
            {
                "arm_group_label": "Rivaroxaban", 
                "description": "Rivaroxaban versus Historical controlled Anticoagulation with Warfarin and Enoxaparin", 
                "intervention_name": "Rivaroxaban", 
                "intervention_type": "Drug", 
                "other_name": "Xarelto"
            }, 
            {
                "arm_group_label": "Warfarin and  Enoxaparin", 
                "description": "Historical Control", 
                "intervention_name": "Warfarin and Enoxaparin", 
                "intervention_type": "Drug", 
                "other_name": "Coumadin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Warfarin", 
                "Enoxaparin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Rivaroxaban", 
            "Warfarin", 
            "Anticoagulation", 
            "Stroke", 
            "Thrombo-embolism", 
            "Bleeding", 
            "Atrial Fibrillation", 
            "Cardioversion"
        ], 
        "lastchanged_date": "October 25, 2013", 
        "location": {
            "contact": {
                "email": "1panton@gmail.com", 
                "last_name": "Pete Antonopoulos, PharmD", 
                "phone": "312-864-5726"
            }, 
            "facility": {
                "address": {
                    "city": "Chicago", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60612"
                }, 
                "name": "Cook County Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Pete Antonopoulos, PharmD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Asimul Ansari, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Dan Ng, PharmD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Anticoagulation With Rivaroxaban in Post Cardioversion Patients", 
        "overall_contact": {
            "email": "1panton@gmail.com", 
            "last_name": "Pete Antonopoulos, PharmD", 
            "phone": "312-864-5726"
        }, 
        "overall_official": [
            {
                "affiliation": "Cook County Hospital", 
                "last_name": "Pete Antonopoulos, PharmD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Cook County Hospital", 
                "last_name": "Asinul Ansari, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of cerebrovascular accidents, thrombus and embolism", 
            "measure": "Thrombosis", 
            "safety_issue": "Yes", 
            "time_frame": "30 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01747746"
        }, 
        "responsible_party": {
            "investigator_affiliation": "John H. Stroger Hospital", 
            "investigator_full_name": "Pete Antonopoulos", 
            "investigator_title": "Clinical Pharmacist- Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Monitor the 30 day mortality rate", 
                "measure": "Mortality", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }, 
            {
                "description": "Hospitalizations for thrombus or adverse events", 
                "measure": "Hospitalizations", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }, 
            {
                "description": "The incidence of major and minor bleeding (as defined under 'safety measures')", 
                "measure": "Bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }
        ], 
        "source": "John H. Stroger Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Cook County Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "John H. Stroger Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}